Key result
The addition of trimetazidine to atorvastatin and conventional therapy significantly improved overall clinical effectiveness (87.5% vs 65.3%) and reduced BNP levels in patients with chronic cardiac failure.
Why the study?
Does trimetazidine added to atorvastatin and standard therapy improve cardiac function and clinical outcomes in patients with chronic cardiac failure?
RCT (n=144)
Randomly allocated
No
Does trimetazidine added to atorvastatin and standard therapy improve cardiac function and clinical outcomes in patients with chronic cardiac failure?
The addition of trimetazidine to atorvastatin and standard heart failure therapy significantly improves cardiac function, reduces BNP levels, and enhances short-term clinical effectiveness in patients with chronic cardiac failure.
Answers are grounded in this paper and cite their sources.
May support trimetazidine addition in chronic heart failure; leaves open need for randomized confirmation.
Purpose: To explore the outcomes and safety of atorvastatin/trimetazidine combination therapy in patients with chronic cardiac failure.Methods: A total of 144 patients with chronic cardiac failure were divided into test group (n = 72) and control group (n = 72). In addition to conventional anti-heart failure treatment, all patients in the two groups received atorvastatin, and those in the test group received, in addition, trimetazidine, for 28 days. The clinical outcomes and safety profiles of the two groups were determined and compared.Results: Compared with pre-treatment stage, the left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular early diastolic peak velocity (E), as well as E to left ventricular end diastolic peak velocity (A) ratio (E/A ratio) for both groups improved significantly after treatment, while A and serum brain natriuretic peptide (BNP) level decreased significantly (all p < 0.05). Moreover, compared with control group, the increases in LVEF, LVFS, E, and E/A ratio of the test group were greater (42.81 ± 3.04 vs 47.97 ± 4.22 %; 31.01 ± 3.19 vs 36.02 ± 3.31 %; 57.44 ± 5.18 vs 61.93 ± 5.42 cm/s; 1.02 ± 0.06 vs 1.19 ± 0.11, respectively), while the decreases in A and BNP level were greater (both p < 0.05) (57.34 ± 4.70 vs 52.37 ± 3.17 cm/s; 589.73 ± 41.19 vs 498.65 ± 30.89 pg/mL, respectively). Therapeutic outcomes were significantly better in the test group than in control group (p < 0.05). Blood pressure, heart rate and serum levels of alanine transaminase (ALT) and creatinine did not differ significantly between the two groups (p > 0.05), but serum potassium and aspartate amino transferase levels were lower in the test group than in the control group (p < 0.05).Conclusion: Atorvastatin combined with trimetazidine effectively reduces BNP level and improves cardiac function in patients with cardiac failure. The safety profile of the combined therapy is good.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2017) conducted an RCT in Chronic cardiac failure (n=144). Trimetazidine added to atorvastatin and conventional therapy vs. Atorvastatin 10 mg daily + conventional therapy was evaluated on Overall clinical effectiveness (improvement in NYHA grade and symptoms) (p=<0.05). The addition of trimetazidine to atorvastatin and conventional therapy significantly improved overall clinical effectiveness (87.5% vs 65.3%) and reduced BNP levels in patients with chronic cardiac failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: